The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

Rheumatology

Volumn 42, Issue 2, 2003, Pages 326-335

  Kobelt, Gisela ^d   Jonsson L ^a   Young, A ^b   Eberhardt, K ^c  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b St Albans City Hospital   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HDI France ^*  (France)

Author keywords

Cost; Cost effectiveness; Infliximab; QALY; RA; Utility

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SWEDEN; UNITED KINGDOM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; METHOTREXATE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SWEDEN;

EID: 0345294739     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg107     Document Type: Article

References (52)

1. Silman A, Hochberg MC. Epidemiology of rheumatic diseases. Oxford: Oxford University Press, 1993.
2. Symmons D, Silman A. The epidemiology of rheumatoid arthritis. In: Wolfe F, Pincus T, eds. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment. New York: Marcel Dekker, 1994:131-50.
3. Meenan R, Yelin E, Nevitt M, Epstain W. The impact of chronic disease: A socioeconomic profile of rheumatoid arthritis. Arthritis Rheum 1981;24:544-9.
4. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;50:1-14.
5. Allaire S, Prashker M, Meenan R. The cost of rheumatoid arthritis. Pharmacoeconomics 1995;6:515-22.
6. Katz P. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995;8:272-8.
7. Pincus T, Callahan L, Sale W, Brooks A, Payne L, Vaughn W. Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27:864-72.
8. Fex E, Larsson B-M, Nived K, Eberhardt K. Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1997;25:44-50.
9. Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of 5 years follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002. In press.
10. Barrett E, Scott D, Wiles N, Symmons D. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology 2000;39:1403-9.
11. Stone C. The lifetime economic cost of rheumatoid arthritis. J Rheumatol 1984;11:819-27.
12. Jönsson B, Kaarela K, Kobelt G. Economic consequences of the progression of rheumatoid arthritis. A Markov model. Stockholm: Stockholm School of Economics, 1997.
13. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
14. Jonsson D, Husberg L. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Heath Care 2000;16:1193-200.
15. McIntosh E. Clinical audit: The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
16. Maini R and the ATTRACT study group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999:354:1932-9.
17. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis. A two-country model to estimate costs and consequences of RA. Arthritis Rheum 2002;46:2310-9.
18. Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
19. Johannesson M. Theory and methods for economic evaluation of health care. Boston: Kluwer Academic Publishers, 1996.
20. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
21. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care. Boston: Kluwer Academic Publishers, 1997.
22. Sonnenberg F, Beck J. Markov models in medical decision making. Med Decis Making 1993;13:322-38.
23. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998; 13:397-409.
24. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheumatism 1980;23:137-45.
25. Eberhardt K, Rydgren L, Petersson H, Wollheim F. Early rheumatoid arthritis-onset, course and prognosis over 2 years. Scand J Rheumatol 1990;17:263-71.
26. Eberhardt K, Fex E. Functional impairment and disability in early rheumatoid arthritis-development over 5 years. J Rheumatol 1995;22:1037-42.
27. Eberhardt K, Fex K. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 1998; 37:1324-9.
28. Lindkvist E, Saxne T, Geborek P, Eberhardt K. Ten-year outcome in a cohort of early rheumatoid arthritis patients-health status, disease process and damage. Ann Rheum Dis 2002;61:1055-9.
29. Young A, Wilkinson P, Talamo J et al. Socioeconomic deprivation and rheumatoid disease. What lessons for the health service? Ann Rheum Dis 2000;59:794-9.
30. Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results from a 5 year follow-up in 732 patients from the Early RA study. Rheumatology 2000; 39:603-33.
31. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
32. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics, University of York, 1995.
33. Brooks R, Group E. EuroQol: the current state of play. Health Policy 1996;37:53-72.
34. National Health Services Executive: The new NHS: 1999 reference costs. Department of Health. www.doh.gov.uk/nhsexec/refcosts.htm.
35. Netten A. Unit costs of health and social care 1999. University of Canterbury Personal Social Services Research Unit (PSSRU). www.ukc.ac.pssru/publications/html.
36. University Hospital Lund. Price list 2002. www.srvn.org/pris02/lund.pdf.
37. British Medical Association. The British National Formulary of Pharmaceutical Products 2000. www.bnf.org.
38. FASS. Läkemedel I Sverige V (Drugs in Sweden). Läkemedelsinformation AB, Stockholm, 2001, www.fas. nu/forms/ffassw/htm.
39. Office for National Statistics. Annual Labour Force Survey 2001. www.hm-treasury.gov.uk.
40. Statistics Sweden. Statistiska Centralbyrån. www.scb.se/ publkat/sm/arbetsmarknad.asp#AM38.
41. Wolfe F, Cathey M. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
42. Harrison B, Symmons D, Brennan P et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol 1996;23:1326-31.
43. Van der Heijde A, Jacobs J, Haanen H, Bijlsma J. Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis? J Rheumatol 1995;22:1466-70.
44. Wiles N, Barrett J, Barrett E, Silman A, Symmons D. Disability in patients with early inflammatory polyarthritis cannot be 'tracked' from year to year: An examination of the hypothesis underlying percentile reference charts. J Rheumatol 1999;26:800-4.
45. Guillemin F, Briancon S, Pourel J. Functional disability in rheumatoid arthritis: two different models in early and established disease. J Rheumatol 1992;19:366-9.
46. Guedes C. Mortality in rheumatoid arthritis. Rev Rheum Engl Ed 1999;66:1895-9.
47. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
48. Soderlin M, Niemimen P, Hakala M. Functional status predicts mortality in a community-based rheumatoid arthritis population. J Rheumatol 1998;25:492-8.
49. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999;58:11-4.
50. Kroot E. No increased mortality in patients with rheumatoid arthritis: up to 10 years follow-up from disease onset. Ann Rheum Dis 2000;59:954-8.
51. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9.
52. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.